U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1684528
•Concept ID:
C4761609
•
Neoplastic Process
Synonym: Locally Advanced Squamous Non-Small Cell Lung Carcinoma

Definition

A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.
Wang A, Jin Y, Cao Z, Lu L, Li Z
Cancer Med 2024 Jan;13(1):e6809. Epub 2023 Dec 20 doi: 10.1002/cam4.6809. PMID: 38124509Free PMC Article
New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
Cameron L, Solomon B
Curr Treat Options Oncol 2015 Oct;16(10):49. doi: 10.1007/s11864-015-0367-z. PMID: 26318457
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Recent clinical studies

Etiology

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y
Lancet Respir Med 2023 Jul;11(7):624-636. Epub 2023 May 5 doi: 10.1016/S2213-2600(23)00135-2. PMID: 37156249
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C
Lancet Oncol 2022 Sep;23(9):1167-1179. Epub 2022 Jul 28 doi: 10.1016/S1470-2045(22)00382-5. PMID: 35908558
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
Lancet Oncol 2021 Jun;22(6):848-857. Epub 2021 May 14 doi: 10.1016/S1470-2045(21)00126-1. PMID: 34000246
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Diagnosis

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.
Bajbouj K, Al-Ali A, Ramakrishnan RK, Saber-Ayad M, Hamid Q
Int J Mol Sci 2021 Oct 28;22(21) doi: 10.3390/ijms222111701. PMID: 34769131Free PMC Article
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
Lancet Oncol 2021 Jun;22(6):848-857. Epub 2021 May 14 doi: 10.1016/S1470-2045(21)00126-1. PMID: 34000246
Lung cancer.
Skřičková J, Kadlec B, Venclíček O, Merta Z
Cas Lek Cesk 2018 Fall;157(5):226-236. PMID: 30441934
Progress and prospects of early detection in lung cancer.
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C
Open Biol 2017 Sep;7(9) doi: 10.1098/rsob.170070. PMID: 28878044Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Therapy

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y
Lancet Respir Med 2023 Jul;11(7):624-636. Epub 2023 May 5 doi: 10.1016/S2213-2600(23)00135-2. PMID: 37156249
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G
J Thorac Oncol 2023 Jan;18(1):93-105. Epub 2022 Sep 29 doi: 10.1016/j.jtho.2022.09.217. PMID: 36184068
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C
Lancet Oncol 2022 Sep;23(9):1167-1179. Epub 2022 Jul 28 doi: 10.1016/S1470-2045(22)00382-5. PMID: 35908558
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
Lancet Oncol 2021 Jun;22(6):848-857. Epub 2021 May 14 doi: 10.1016/S1470-2045(21)00126-1. PMID: 34000246
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Prognosis

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
Du C, Chen Y, Zhou Y, Zheng D, Zhao J, Tang J, Wu Y, Tu Z
BMC Cancer 2023 Dec 21;23(1):1260. doi: 10.1186/s12885-023-11745-x. PMID: 38129808Free PMC Article
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, Lievens Y, Surmont V, Brochez L, Reynders D, Danckaert W, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Ost P
JAMA Oncol 2023 Sep 1;9(9):1205-1213. doi: 10.1001/jamaoncol.2023.2132. PMID: 37410476Free PMC Article
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L
Cancer Commun (Lond) 2022 Dec;42(12):1314-1330. Epub 2022 Nov 6 doi: 10.1002/cac2.12385. PMID: 36336841Free PMC Article
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
Progress and prospects of early detection in lung cancer.
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C
Open Biol 2017 Sep;7(9) doi: 10.1098/rsob.170070. PMID: 28878044Free PMC Article

Clinical prediction guides

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L
Cancer Commun (Lond) 2022 Dec;42(12):1314-1330. Epub 2022 Nov 6 doi: 10.1002/cac2.12385. PMID: 36336841Free PMC Article
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
Lancet Oncol 2021 Jun;22(6):848-857. Epub 2021 May 14 doi: 10.1016/S1470-2045(21)00126-1. PMID: 34000246
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, Li B, Mok T
Int J Cancer 2021 May 1;148(9):2313-2320. Epub 2020 Dec 9 doi: 10.1002/ijc.33399. PMID: 33231285Free PMC Article
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977

Recent systematic reviews

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
Cheng M, Shao Y, Li L, Jiang M, Song Z
BMC Cancer 2024 Mar 6;24(1):312. doi: 10.1186/s12885-024-12043-w. PMID: 38448878Free PMC Article
The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S
BMC Pulm Med 2023 Dec 8;23(1):495. doi: 10.1186/s12890-023-02755-3. PMID: 38066549Free PMC Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA
Cochrane Database Syst Rev 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. PMID: 27223332
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R
Health Technol Assess 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. PMID: 23886301Free PMC Article
A systematic overview of radiation therapy effects in non-small cell lung cancer.
Sirzén F, Kjellén E, Sörenson S, Cavallin-Ståhl E
Acta Oncol 2003;42(5-6):493-515. doi: 10.1080/02841860310014453. PMID: 14596509

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...